Evidence map›Paper›PMID 27170005›Full record

ArticleReproductive biology and endocrinology : RB&E2016

Osmotic-shock produced by vitrification solutions improves immature human oocytes in vitro maturation.

Inmaculada Molina, Judith Gómez, Sebastián Balasch, Nuria Pellicer, Edurne Novella-Maestre

Open access · goldAbstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Immature Oocyte for Fertility Preservation.Frontiers in endocrinology · 2019
    Review
  11. OocyteTurkish journal of obstetrics and gynecology · 2018
    Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Inmaculada MolinaUnidad de Reproducción Humana, Área de Salud de la Mujer, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Judith GómezUnidad de Reproducción Humana, Área de Salud de la Mujer, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Sebastián BalaschDepartamento de Estadística e Investigación Operativa Aplicadas y Calidad, Universidad Politécnica de Valencia, Valencia, Spain.
Nuria PellicerFundación Instituto Valenciano de Infertilidad, Instituto Universitario IVI, Valencia, Spain.
Edurne Novella-MaestreUnidad de Genética, Torre A planta 4º, Hospital Universitario y Politécnico La Fe, Avenida de Fernando Abril Martorell, nº 106, 46026, Valencia, Spain. edurnenovella@yahoo.es.
Hospital Universitari i Politècnic La Fe · ESUniversitat Politècnica de València · ESValencian Infertility Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring cytoplasmic oocyte maturation, Ca(2+) currents are vital for regulating a broad range of physiological processes. Recent studies have demonstrated that DMSO and EG cause large transient increases in intracellular Ca(2+) in mouse oocytes. The CP used in vitrifying protocols also increases the intracellular calcium transient. The aim of this study is to evaluate the effects of vitrifying time (before and after IVM) and exposure to the vitrification solutions and ionomycin on oocyte quality and embryonic development.

methods221 GV-oocytes unsuitable for IVF-ICSI cycles were randomly distributed into one of the following three groups. G1 (control group): 41 GV-oocytes IVM until MII; G2: 43 oocytes vitrified at GV stage and IVM until MII stage; and G3: 53 GV-oocytes IVM until MII and then vitrified. In order to clarify the effect of vitrification solutions (VS) on human oocyte IVM through the intracellular Ca(2+) oscillation, the following two groups were also included. G4: 43 GV-oocytes exposed to VS and IVM until MII; and G5: 41 GV-oocytes exposed to ionomycin and IVM until MII. All GV-oocytes that reached MII-stage were parthenogenetically activated to assess oocyte viability. IVM was performed in IVF-medium (24-48 h). Chemical treatment (ionomycin) and osmotic treatment (vitrification solutions) were performed without liquid-N2 immersion. The following rates were evaluated: survival (SR), in-vitro maturation (IVMR), activation (AR), development to 2-cell (DRC), development to morula (DRCM) and development to blastocyst (DRB). Ratios between the different treatment groups were compared using contingency tables analysis (chi-square test).

resultsA high survival rate was obtained in G2 (95.5 %) and G4 (96.6 %). In-vitro maturation rate was significantly higher for G4 (86 %) and G2 (83.7 %) compared to G1 (63.4 %), G3 (56.6 %) and G5 (48.8 %). DRCM was significantly higher for G1 and G2 compared to G3 (G1: 15.8 %, G2: 20.7 % and G3: 0 %). DRB was only obtained for the oocytes vitrified before IVM (G2: 3.4 %). AR was also significantly higher for G2 and G4 compared to G5 (G2: 80.5 %, G4: 86.5 % and G5: 55 %). DRCM and DRB were only obtained in G2 and G4. DRCM was significantly higher for oocytes vitrified at GV stage (G2) and for oocytes exposed to the VS in G4 compared to the oocytes exposed to the ionomycin in G5 (G2: 20.7 %; G4: 37.5 % and G5: 0 %).

conclusionsVitrifying GV-oocytes improves their IVM. Further investigation could look to increase the oocyte pool and improve fertility preservation options.

Indexed as

Osmotic PressureVitrificationAdultCalciumCell SurvivalCulture MediaEmbryonic DevelopmentFemaleFertility PreservationHumansIn Vitro Oocyte Maturation TechniquesOocytesCalciumCulture MediaContingency tablesFertility preservationImmature oocytesIn vitro maturationVitrification

Identifiers

PMID27170005
PMCPMC4866294
OpenAlexW2376373561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.